3 results on '"Christiane Broussolle"'
Search Results
2. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy
- Author
-
Sandra Vukusic, D. Maillet, Romain Marignier, L. Pinède, Christian Confavreux, Pascal Sève, Géraldine Androdias, Christiane Broussolle, Equipe 1, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Laboratoire Énergies et Mécanique Théorique et Appliquée (LEMTA ), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neuro-oncologie et neuro-inflammation, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe 14, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
MESH: Sarcoidosis ,Adult ,Male ,medicine.medical_specialty ,Sarcoidosis ,medicine.drug_class ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Mycophenolate ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Maintenance therapy ,Muscular Diseases ,Central Nervous System Diseases ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,MESH: Treatment Outcome ,MESH: Mycophenolic Acid ,Aged ,Retrospective Studies ,MESH: Aged ,MESH: Humans ,business.industry ,MESH: Muscular Diseases ,Neurosarcoidosis ,Retrospective cohort study ,MESH: Adult ,MESH: Retrospective Studies ,Mycophenolic Acid ,medicine.disease ,MESH: Central Nervous System Diseases ,MESH: Male ,3. Good health ,Surgery ,Prior Therapy ,Treatment Outcome ,Corticosteroid ,Female ,Neurology (clinical) ,MESH: Immunosuppressive Agents ,business ,MESH: Female ,030217 neurology & neurosurgery ,Immunosuppressive Agents ,Hormone - Abstract
International audience; OBJECTIVE: To describe effectiveness, steroid-sparing effect, and tolerance of the antiproliferative immunosuppressant mycophenolate mofetil (MMF) in neurosarcoidosis. METHODS: We describe a retrospective case series of 10 consecutive patients with a diagnosis of neurosarcoidosis who were treated with MMF, alone or in association with corticosteroids, in our teaching hospital. RESULTS: At the time of our study, the mean duration of MMF treatment was 21 months. All but one patient with CNS involvement (n = 8) were in remission (except for hormonal dysfunction) which was complete in 6 patients. MMF was efficient as single-agent induction therapy in one patient. The 3 patients who received MMF as a maintenance therapy after initial response to corticosteroids did not relapse even though steroids were stopped. Out of 4 subjects who demonstrated insufficient response to prior therapy including corticosteroids and immunosuppressive agents, 3 demonstrated significant clinical and radiologic improvement. However, the 2 patients who presented muscular sarcoidosis did not respond to MMF. Among patients treated with steroids at MMF introduction and after excluding those with sarcoid myopathy, the mean dose of corticosteroids was 6 mg/day at the end of the follow-up while it was 59 mg/day at the initiation of MMF. No significant side effects were observed. CONCLUSIONS: These data suggest that MMF is effective in CNS sarcoidosis but not in sarcoid myopathy, with a corticosteroid sparing effect and a better tolerance profile than other immunosuppressive agents.
- Published
- 2011
3. Progressive multifocal leukoencephalopathy in patients with sarcoidosis
- Author
-
Mohamed Hamidou, Antoine Néel, Jean Paul Bouwyn, Christiane Broussolle, David Maltête, Romain Lefaucheur, Bertrand Bourre, Patrick Ahtoy, Pascal Sève, and Yvan Jamilloux
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Progressive multifocal leukoencephalopathy ,JC virus ,medicine.disease ,medicine.disease_cause ,medicine ,In patient ,Neurology (clinical) ,Sarcoidosis ,medicine.symptom ,Alzheimer's disease ,Older people ,business ,Confusion ,Cause of death - Abstract
Editors' Note: In response to the article “Progressive multifocal leukoencephalopathy in patients with sarcoidosis,” Drs. Lefaucheur et al. report a patient with sarcoidosis developing possible progressive multifocal leukoencephalopathy despite 4 negative JC virus CSF PCRs and being treated with mirtazapine and IV immunoglobulin. Authors Jamilloux et al. comment on the case. In reference to “Contribution of Alzheimer disease to mortality in the United States,” Dr. Campbell-Taylor calls attention to the confusion surrounding the completion and interpretation of death certificates. Authors James et al. clarify their methodology and make the insightful point that pinpointing a single cause of death may not accurately characterize the process of dying for many older people. —Megan Alcauskas, MD, and Robert C. Griggs, MD We read the article by Jamilloux et al.1 with interest. As …
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.